January 27, 2023 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).
MIPS Quality Measures Dashboard
The MIPS Quality Measures Dashboard has been updated to reflect the below refinements for:
| Measure | Update | Practice Impact |
|---|---|---|
| PIMSH 2: Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) | A refinement has been made to better attribute patients to the clinician most appropriate. The refinement requires a patient to have 2 qualifying E/M visits with a clinician during the measurement period to establish that the patient is under the clinician’s care. Numerator met will be attributed to the clinician who ordered the GCSF drug within 30 days of the patient receiving chemotherapy. | Practices may notice changes to the numerator and denominator due to the two E/M visit requirement not being met. |
| PIMSH 4: Patient-Reported Pain Improvement | A refinement has been made to the numerator criteria. For a patient who has an elevated pain score of 3 or greater, documentation of a decreased pain level within 30 days during a non-E/M visit will meet the numerator.
A refinement has also been made to the denominator to exclude patients from the denominator who are on hormonal treatment only (i.e., not on active chemotherapy or radiation treatment). |
Practices may notice an increase in the numerator and a decrease in the denominator due to this update. Removing patients receiving hormonal treatment from the denominator decreases the denominator. |
Status of Dashboard Updates for 2022
CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2022 requirements. The measures listed below either have no 2022 update required or have been updated.
| Measure | Description |
|---|---|
MIPS Quality Measures Dashboard |
|
| #047 | Advance Care Plan |
|
#104 |
Combination Androgen Deprivation Therapy for Prostate |
| #110 | Preventive Care and Screening: Influenza Immunization |
| #128 | Body Mass Index (BMI) Screening and Follow-Up Plan |
| #130 | Current Medications Documentation |
| #134 | Depression Screening |
| #143 | Pain Intensity Quantified |
| #144 | Pain Care Plan |
| #226 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
|
#236 |
Controlling High Blood Pressure |
| #374 | Closing the Referral Loop |
| #451 | RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy |
| #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
|
#457 |
Patients Admitted to Hospice for < 3 Days |
| PIMSH#1 | Advance Care Planning in Metastatic Cancer |
| PIMSH#2 | Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
| PIMSH#4 | Patient-Reported Pain Improvement |
|
PIMSH#8 |
Mutation Testing for Lung Cancer |
| PIMSH#9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH#10 | Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs |
|
PIMSH#12 |
COVID-19 Vaccinations |
OCM Performance Measures Dashboard 1H 2022 |
|
| OCM 4A | Pain Intensity Quantified |
| OCM 4B | Plan of Care for Pain |
| OCM5 | Depression Screening |